At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib, Multicenter, Randomized, Double-blind, Placebo-controlled Parallel Group Clinical Study Evaluating the Efficacy and Safety of Megestrol Acetate Oral Suspension in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy
In Brief
A Phase 1 clinical trial evaluating Low dose of Megestrol Acetate Oral Suspension combined with standard therapy, Medium dose of Megestrol Acetate Oral Suspension combined with standard therapy, and 2 other interventions for Efficacy and 3 related conditions. Not yet recruiting, targeting 132 participants across 1 site.
Detailed Summary
To evaluate the efficacy of Megestrol Acetate Oral Suspension in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy in Malignant Solid Tumor Patients
Study Details
Timeline
Interventions
A single dose of 312.5 mg/day, administered once daily (QD) for 7 consecutive days.
A single dose of 625 mg/day, administered once daily (QD) for 7 consecutive days.
A single dose of 937.5 mg/day, administered once daily (QD) for 7 consecutive days.
A single dose of 5 mL/day, administered once daily (QD) for 7 consecutive days.